Marker Therapeutics Inc

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HOUSTON, Aug. 10, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the second quarter ended June 30, 2021.   "Marker accomplished a number of strategic goals and clinical milestones this quarter, including completing the safety lead-in portion of our Company-sponsored Phase 2 trial investigating Marker's MultiTAA-specific T cell therapy in post-transplant acute myeloid leukemia, or AML," said Peter L.

Marker Therapeutics Reports Second Quarter 2021 Operating and Financial Results

HOUSTON, July 28, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the Company's new cGMP manufacturing facility in Houston, TX, located near the George Bush Intercontinental Airport, is fully operational. The facility will manufacture Marker's MultiTAA-specific T cell products for the Company's Phase 2 acute myeloid leukemia (AML) trial as well as future hematological and solid tumor trials, in addition to producing the potential commercial supply of any approved products.

Marker Therapeutics Announces Opening of New cGMP Manufacturing Facility

HOUSTON, July 6, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced completion of the six-patient safety lead-in portion of the Company's Phase 2 trial of MT-401, its lead MultiTAA-specific T cell product candidate, for the treatment of post-transplant acute myeloid leukemia (AML). "We are pleased with the results of the safety lead-in portion of the trial, in which all six patients met the safety endpoints following infusion of our MultiTAA-specific T cell therapy," said Mythili Koneru, M.D.

Marker Therapeutics Announces Completion of Safety Lead-In Portion of Phase 2 Study in Post-Transplant AML

HOUSTON, June 16, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its Chief Financial Officer, Anthony H. Kim, will present at the upcoming virtual Raymond James Human Health Innovation Conference on Monday, June 21, 2021 at 9:20 a.m.

Marker Therapeutics to Present at the Virtual Raymond James Human Health Innovation Conference

Iterum Therapeutics Plc

Sesen Bio Inc.

Tellurian

VistaGen Therapeutics

Analysts say these are penny stocks to buy right now & have bullish targets to back it up. The post 5 Penny Stocks Analysts Say To Buy With Targets Up To 219% Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks Analysts Say To Buy With Targets Up To 219% Right Now

Color Star Technology

Obalon Therapeutics

Top penny stocks to buy today? Check these 3 out for your watchlist The post Top Penny Stocks to Buy Today?

Top Penny Stocks to Buy Today? Here's 3 to Watch in 2021

Marker Therapeutics, Inc. (MRKR) CEO Peter Hoang on Q1 2021 Results - Earnings Call Transcript

HOUSTON, May 12, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the first quarter ended March 31, 2021.   "We had a productive first quarter supported by our recently completed financing, strengthening our overall cash position and enabling continued growth and expansion of our Multi-TAA pipeline," said Peter L.

Marker Therapeutics Reports First Quarter 2021 Operating and Financial Results

HOUSTON, April 29, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that it will host a conference call and webcast on Wednesday, May 12, 2021 at 5:00 p.m. Eastern Time to review its first quarter 2021 financial and operating results and provide a corporate update.

Marker Therapeutics to Host First Quarter 2021 Operating and Financial Results Conference Call and Webcast on Wednesday, May 12, 2021

HOUSTON, April 27, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that it will present data detailing a new robotics technology to aid in multi-tumor-associated antigen (mTAA)-specific T cell therapy manufacturing at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place virtually May 11-14, 2021. The data will be presented by lead author Anastasiya Smith, Ph.D.

Marker Therapeutics to Present Multi-Tumor-Associated Antigen (mTAA)-Specific T Cell Manufacturing Robotics Data at the 2021 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Today, we take an in-depth look at clinical-stage immuno-oncology company named Marker Therapeutics. The company has multiple 'shots on goal', heavy insider buying and recently addressed its funding needs.

Marker Therapeutics Gets A 'Thumbs Up'

Marker Therapeutics: Undervalued Cancer Therapeutics With High Potential

Investors need to pay close attention to Marker Therapeutics (MRKR) stock based on the movements in the options market lately.

Do Options Traders Know Something About Marker Therapeutics (MRKR) Stock We Don't?

Aytu BioScience

Bionano Genomics

Citius Pharmaceuticals

Denison Mines

Hall of Fame Resort & Entertainment

Ideanomics Inc

Neos Therapeutics

Zomedica

Reddit penny stocks continue to be of interest to risky investors and InvestorPlace is looking at the top ones for Monday. The post 10 Reddit Penny Stocks Seeing the Most Chatter Today appeared first on InvestorPlace.

10 Reddit Penny Stocks Seeing the Most Chatter Today

Dyadic International Inc., DE

Odonate Therapeutics

Odonate Therapeutics, Inc. (NASDAQ: ODT), Dyadic International, Inc. (NASDAQ: DYAI) and Marker Therapeutics, Inc. (NASDAQ: MRKR) are among the early biotech movers in Monday's session. Odonate to Shut Shop: Odonate, an oncology-focused pharma company, said it is discontinuing the development of tesetaxel following feedback from the Food and Drug Administration in a pre-New Drug Application meeting.

Why Odonate, Marker Therapeutics and Dyadic Are Moving Monday

The stock price of Marker Therapeutics, Inc. (NASDAQ: MRKR) has increased by over 15% pre-market. This is why it happened.

MRKR Stock Price Increases Over 15% Pre-Market: Why It Happened

The stock price of Marker Therapeutics Inc. (NASDAQ: MRKR) increased by 34.44% on March 19. This is why it happened.

MRKR Stock Price Increased 34.44%: Why It Happened

Bristol-Myers

Pfizer

BioCryst Pharmaceuticals

Pacira Pharmaceuticals

ProQR Therapeutics

Rubius Therapeutics Inc

Zealand Pharma

Biotech stocks reversed course in the week ended March 19 amid mixed news flow on data readouts and lackluster broader market performance. Rubius Therapeutics, Inc. (NASDAQ: RUBY) was among the biggest gainers of the week after the biopharma reported positive Phase 1/2 data for its RTX-240 in solid tumors.

FDA Decisions For Pfizer, Eli Lilly And Bluebird Bio, Bristol-Meyers Squibb, Plus New Data And Earnings

Alector Inc

Clovis Oncology

Clovis Oncology, Inc. (NASDAQ: CLVS), Marker Therapeutics, Inc. (NASDAQ: MRKR) and Alector, Inc. (NASDAQ: ALEC) are among the biggest biotech gainers Friday. Clovis Jumps On Ovarian Cancer Data: Clovis announced positive results for the Phase 3 study of Rubraca in ovarian cancer.

Why Clovis Oncology, Marker Therapeutics, Alector Are Rallying Friday

The stock price of TapImmune Inc. (NASDAQ: MRKR) increased by over 20% pre-market. This is why it happened.

MRKR Stock Price Increases Over 20% Pre-Market: Why It Happened

HOUSTON, March 16, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the closing of an underwritten public offering of 32,282,857 shares of its common stock at a public offering price of $1.75 per share. The gross proceeds to Marker from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $56.5 million.

Marker Therapeutics, Inc. Announces Closing of Public Offering of Common Stock

HOUSTON, March 15, 2021 /PRNewswire/ --  Marker Therapeutics, Inc.  (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its President and Chief Executive Officer, Peter L. Hoang, will present at the upcoming Virtual Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17, 2021 at 3:10 p.m.

Marker Therapeutics to Present at the Virtual Oppenheimer 31st Annual Healthcare Conference

Marker Therapeutics Inc (NASDAQ: MRKR) priced an underwritten public offering of 28.57 million common shares at $1.75 per share, representing a 31% discount from the last close price of $2.53 on Thursday.  The company will raise approximately $50 million in gross proceeds from the offering.

Marker Therapeutics Stock Plunges On Capital Raise At 31% Discount

HOUSTON, March 12, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the pricing of an underwritten public offering of 28,572,000 shares of its common stock at a public offering price of $1.75 per share. The gross proceeds to Marker from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $50.0 million.

Marker Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock

HOUSTON, March 11, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Marker expects to grant the underwriters a 30-day option to purchase additional shares of its common stock.

Marker Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

News for Marker Therapeutics Inc Stock (MRKR)